2023
482 Triple Therapy Versus Dual Antiplatelet Therapy for Dolichoectatic Vertebrobasilar Fusiform Aneurysms Treated With Flow Diverters: The Last Frontier?
Siddiqui A, Monteiro A, Hanel R, Kan P, Mohanty A, Cortez G, Rabinovich M, Matouk C, Sujijantarat N, Romero C, Stone J, Ebersole K, Fry L, Natarajan S, Thomson B, Ortega-Gutierrez S, Vivanco-Suarez J, Wakhloo A, Levy E. 482 Triple Therapy Versus Dual Antiplatelet Therapy for Dolichoectatic Vertebrobasilar Fusiform Aneurysms Treated With Flow Diverters: The Last Frontier? Neurosurgery 2023, 69: 103-104. DOI: 10.1227/neu.0000000000002375_482.Peer-Reviewed Original ResearchTriple therapy groupDual antiplatelet therapyVertebrobasilar fusiform aneurysmsBrainstem compressionIschemic strokeAneurysm characteristicsFusiform aneurysmsFlow diversionIschemic stroke ratePoor natural historyRetrospective data collectionOverall rateAntiplatelet therapyBaseline disabilityHemorrhagic complicationsRadial access useTriple therapyAngiographic outcomesClinical outcomesClinical presentationHigh morbimortalityAdjunctive coilingSimilar patientsMedian numberPerforator occlusion
2022
P-017 Triple therapy versus dual antiplatelet therapy for dolichoectatic vertebrobasilar fusiform aneurysms treated with flow-diverters: the last frontier?
Siddiqui A, Monteiro A, Hanel R, Kan P, Mohanty A, Cortez G, Rabinovich M, Matouk C, Sujijantarat N, Ebersole K, Fry L, Natarajan S, Owusu-Adjei B, Ortega-Gutierrez S, Vivanco-Suarez J, Wakhloo A, Levy E. P-017 Triple therapy versus dual antiplatelet therapy for dolichoectatic vertebrobasilar fusiform aneurysms treated with flow-diverters: the last frontier? 2022, a59.1-a59. DOI: 10.1136/neurintsurg-2022-snis.89.Peer-Reviewed Original Research